Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.30
-0.16 (-2.48%)
At close: Apr 28, 2026, 4:00 PM EDT
6.35
+0.05 (0.79%)
Pre-market: Apr 29, 2026, 8:02 AM EDT
Taysha Gene Therapies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 9.77 | 8.33 | 15.45 | 2.5 | - | |
| Revenue Growth (YoY) | 17.28% | -46.07% | 517.55% | - | - | |
| Gross Profit | 9.77 | 8.33 | 15.45 | 2.5 | - | |
| Selling, General & Admin | 33.87 | 28.95 | 30.05 | 37.36 | 41.32 | |
| Research & Development | 86.4 | 66 | 56.78 | 91.17 | 131.94 | |
| Operating Expenses | 120.27 | 94.95 | 86.83 | 128.53 | 173.27 | |
| Operating Income | -110.5 | -86.62 | -71.37 | -126.03 | -173.27 | |
| Interest Expense | -0.06 | -0.1 | -5 | -3.8 | -1.43 | |
| Interest & Investment Income | 9.22 | 6.94 | 3.57 | 0.25 | 0.17 | |
| Other Non Operating Income (Expenses) | -1.49 | -0.09 | -34.77 | -0.02 | - | |
| EBT Excluding Unusual Items | -102.83 | -79.88 | -107.57 | -129.59 | -174.52 | |
| Asset Writedown | - | -4.84 | -1.07 | -36.42 | - | |
| Other Unusual Items | -6.17 | -4.58 | -2.94 | - | - | |
| Pretax Income | -109 | -89.3 | -111.57 | -166.01 | -174.52 | |
| Net Income | -109 | -89.3 | -111.57 | -166.01 | -174.52 | |
| Net Income to Common | -109 | -89.3 | -111.57 | -166.01 | -174.52 | |
| Shares Outstanding (Basic) | 320 | 250 | 116 | 44 | 38 | |
| Shares Outstanding (Diluted) | 320 | 250 | 116 | 44 | 38 | |
| Shares Change (YoY) | 27.82% | 115.41% | 164.20% | 16.74% | 113.13% | |
| EPS (Basic) | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | |
| EPS (Diluted) | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | |
| Free Cash Flow | -93.83 | -81.6 | -76.89 | -109.01 | -132.35 | |
| Free Cash Flow Per Share | -0.29 | -0.33 | -0.66 | -2.48 | -3.52 | |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | |
| Operating Margin | -1130.65% | -1039.49% | -461.94% | -5037.05% | - | |
| Profit Margin | -1115.27% | -1071.62% | -722.06% | -6635.25% | - | |
| Free Cash Flow Margin | -960.07% | -979.23% | -497.62% | -4356.88% | - | |
| EBITDA | -109.35 | -85.38 | -70 | -124.86 | -172.78 | |
| D&A For EBITDA | 1.15 | 1.25 | 1.37 | 1.17 | 0.49 | |
| EBIT | -110.5 | -86.62 | -71.37 | -126.03 | -173.27 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.